Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-3945-z
Abstract: PurposePeptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and… read more here.
Keywords: study; toxicity; dota octreotate; 177lu dota ... See more keywords
Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00270
Abstract: Currently, the 5-year survival rate for patients with advanced hepatocellular carcinoma (HCC) is very low. Therefore, there is an urgent need to find new strategies for the treatment of HCC. TMTP1 (NVVRQ) is a tumor-homing… read more here.
Keywords: hepatocellular carcinoma; 177lu dota; tmtp1; dota tmtp1 ... See more keywords
Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00424
Abstract: Fibroblast activation protein (FAP), a fundamental component of the tumor stroma, is overexpressed in cancer-associated fibroblasts (CAFs). As a promising theranostic probe, we evaluated whether the FAP inhibitor (FAPI) dimer (DOTA-2P[FAPI]2) is more effective than… read more here.
Keywords: fapi; dota fapi; retention; 177lu dota ... See more keywords
New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.3c00117
Abstract: PET imaging of the glucagon-like peptide-1 receptor (GLP-1R) using radiolabeled exendin is a promising imaging method to detect insulinomas. However, high renal accumulation of radiolabeled exendin could hamper the detection of small insulinomas in proximity… read more here.
Keywords: renal retention; 177lu dota; nota exendin; 68ga nota ... See more keywords
Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2065146
Abstract: Abstract Objective To explore the healthcare resource utilization (HCRU) and costs for patients with progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [177Lu]Lu-DOTA-TATE and matched patients treated with somatostatin analogs (SSAs), chemotherapy, or targeted therapies. Methods… read more here.
Keywords: 177lu dota; utilization; group; dota tate ... See more keywords
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Sign Up to like & getrecommendations! Published in 2020 at "EJNMMI Research"
DOI: 10.1186/s13550-020-00637-x
Abstract: Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed… read more here.
Keywords: dota miltuximab; antibody; miltuximab; 177lu dota ... See more keywords
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.tps5109
Abstract: TPS5109 Background: The cell surface glycoprotein prostate-specific membrane antigen (PSMA) has proven to be an ideal therapeutic target in prostate cancer (PC) as it is highly expressed by malignant prostate cells.1,2 177Lu-DOTA-HuJ591-CHO (TLX591) is a… read more here.
Keywords: biodistribution dosimetry; tlx591; safety; 177lu dota ... See more keywords
In vivo and in vitro evaluation of 177Lu-labeled DOTA-2-deoxy-D-glucose in mice. A novel radiopharmaceutical agent for cells imaging and therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Hellenic journal of nuclear medicine"
DOI: 10.1967/s002449911002
Abstract: OBJECTIVE Incorporation of lutetium-177 (177Lu) into suitable molecules that are implicated in cancer pathology represents a promising approach for the diagnosis and treatment of cancer. The goal of the present study was to develop a… read more here.
Keywords: radiopharmaceutical agent; dota; 177lu labeled; 177lu dota ... See more keywords
SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a 177Lu-DOTA-Integrin αvβ6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.684713
Abstract: Introduction Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant neoplasms, as many cases go undetected until they reach an advanced stage. Integrin αvβ6 is a cell surface receptor overexpressed in PDAC. Consequently,… read more here.
Keywords: capan; biodistribution; dota integrin; integrin ... See more keywords
In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.849338
Abstract: Carcinoembryonic antigen (CEA) is an antigen that is highly expressed in colorectal cancers and widely used as a tumor marker. 131I and 90Y-radiolabeled anti-CEA monoclonal antibodies (mAbs) have previously been assessed for radioimmunotherapy in early… read more here.
Keywords: cancer; dota m5a; 177lu dota; anti ... See more keywords
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10123102
Abstract: Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still… read more here.
Keywords: 177lu dota; tate; dota tate; treatment ... See more keywords